Collaborative Research Consortia

International and interdisciplinary research group investigating consciousness, including altered-state and psychedelic-relevant domains.

Barcelona Computational Foundation is a non-profit research foundation focused on understanding and recreating life, brains, and minds as computational phenomena.

CZECRIN (Czech Clinical Research Infrastructure Network) is the Czech national node of the pan-European ECRIN-ERIC research infrastructure, supporting non-commercial academic clinical trials across Czech hospitals and research institutions. It has actively showcased the PSIKET001 and PSIKET002 trials — landmark double-blind comparisons of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — as flagship examples of Czech psychedelic clinical innovation.

The Global Coalition for Adaptive Research (GCAR) is a US non-profit that serves as regulatory sponsor for adaptive platform trials, including GBM AGILE (glioblastoma) and the DOD-backed M-PACT (NCT05422612), which simultaneously evaluates multiple pharmacotherapies for PTSD in active-duty service members and veterans. GCAR modernizes drug development by replacing ineffective arms with new candidates within a single master protocol.

European doctoral network training the next generation of psychedelic therapy researchers through coordinated cross-institution programs.

The International Society for Research on Psychedelics (ISRP) is a professional scientific society that connects researchers across disciplines to advance rigorous psychedelic science, collaboration, and dissemination.

The National Network of Depression Centers is a U.S.-based nonprofit consortium of academic medical centers and mental health programs focused on depression, bipolar disorder, and related mood disorders. It operates nationally across member sites in the United States and is centered in Ann Arbor, Michigan. Its core activities include collaborative research, clinical education, outreach, and network-based improvement of evidence-based care. In the psychedelic-adjacent space, NNDC appears primarily as a mood-disorders research and clinical collaboration network rather than a dedicated psychedelic policy group. Its ketamine task group was created to share information and experience as ketamine and esketamine clinics expanded across the network, and NNDC has also reported on the BIO-K biomarker study of ketamine for major depression. This makes it relevant to researchers, clinicians, and funders working on interventional psychiatry, treatment-resistant depression, and evidence-building around regulated access pathways.

European collaborative research project focused on psychedelic-assisted therapy in palliative care contexts.

The Psychedelic Data Society is a US-based citizen-science nonprofit managing the Psychedelic Data Project, a global harm reduction and research initiative that collects participant-contributed data to accelerate psychedelic science and inform evidence-based drug policy reform.

Reconnect Foundation is a Swiss charitable organization that operates from Switzerland and supports work at the intersection of consciousness research, healthcare accessibility, and ecosystem conservation. Its public materials describe an emphasis on open science, support for academic research, and collaboration with Indigenous Peoples and local communities. It also says the foundation was established by the founders of Reconnect Labs, a Swiss biotech company based at the University of Zurich. In psychedelic-adjacent work, Reconnect Foundation says it supports consciousness research using psychedelics and other consciousness-altering methods, along with mindfulness and ethnobotanical research into ancestral practices. It also runs a benefit-sharing and ecosystem restoration effort focused on Indigenous rights, biocultural conservation, and consultation with Indigenous leaders and partner NGOs in the Amazon region. Documented collaborators named on its site include the Indigenous Medicine Conservation Fund, ICEERS, and El Puente.

The Swiss Medical Society for Psycholytic Therapy, now presented on its site as SÄPT, is a Switzerland-based interdisciplinary medical society founded in 1986. It primarily serves German-speaking clinicians and related therapeutic professionals, including psychiatry, psychotherapy, neurology, palliative care, general medicine, psychology, and other therapeutic fields. Its core activities include professional exchange, training, and supporting medically supervised psychedelic-assisted therapy. SÄPT positions itself as a field-building organization for psychedelic-assisted therapy in Switzerland, with a focus on research support, quality standards, and professional education. Its website states that members have supported studies involving MDMA-assisted psychotherapy and LSD-assisted psychotherapy, and it currently lists ongoing or recent study and training announcements, including LSD studies for life-limiting illness, cluster headache, alcohol dependence, and older adults, plus an institutional PAT working group and treatment recommendations through IG PAT. It also provides patient-facing information on where psychedelic-assisted therapy may be available and on support options for difficult psychedelic experiences, which makes it a practical access and referral-adjacent stakeholder rather than a broad public advocacy group. Historically, SÄPT reports that five therapists received Swiss federal exception permits from 1988 to 1993 to conduct psychedelic-assisted therapy with MDMA and LSD in private practice, treating about 170 patients. Today it appears to operate mainly as a professional society that advances psycholytic therapy through education, research collaboration, ethical standards, and guidance for clinicians working within Switzerland’s restricted medical-use framework. Potential collaboration areas include clinical research, training, treatment standards, institutional implementation, and patient information pathways for researchers, clinicians, funders, policy groups, and patient communities.

A national nonprofit scientific society of healthcare professionals, researchers, and patient advocates dedicated to advancing pain research, education, and treatment in Canada. The Canadian Pain Society promotes the understanding and effective management of acute and chronic pain through scientific exchange, advocacy, and continuing education.

A nonprofit neuroimaging and neuroinformatics research organization based in Albuquerque, New Mexico, affiliated with the University of New Mexico. The Mind Research Network specializes in psychiatric and neurological brain imaging research using advanced MRI technologies, studying conditions including schizophrenia, addiction, PTSD, and traumatic brain injury.

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.

University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.